Download PDF

1. Company Snapshot

1.a. Company Description

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally.The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation.It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases.


In addition, the company supplies diagnostic instruments and reagents.The company was founded in 1896 and is headquartered in Basel, Switzerland.

Show Full description

1.b. Last Insights on ROG

Roche Holding's recent momentum is driven by a series of positive developments. The company's Phase III results for investigational drugs fenebrutinib in multiple sclerosis and Gazyva/Gazyvaro in systemic lupus erythematosus showed significant clinical benefits. Additionally, Roche announced FDA approval for Gazyva in lupus nephritis and unveiled positive results in breast cancer treatment. These achievements reflect Roche's research momentum in oncology, autoimmune diseases, and diagnostics. Analysts have modestly increased their fair value estimate, citing promising clinical trial outcomes and strategic partnerships.

1.c. Company Highlights

2. Roche's 2025 Results: Strong Pharma Growth and Pipeline Progress

Roche's 2025 full-year results showed a 7% group sales growth, driven by a 9% increase in Pharma sales to CHF 47.7 billion, while Diagnostics sales grew 2% to CHF 13.8 billion, impacted by China healthcare pricing reforms. Core operating profit rose 13% with a core operating margin increase of 1.9 percentage points, and core EPS grew 11%. The company's financial results included a 7% sales increase, with IFRS net income up 58% to CHF 16.2 billion, driven by operating profit growth.

Publication Date: Feb -02

📋 Highlights
  • Pharma Sales & Profit Growth:: Pharma division grew 9% to CHF 47.7B, with core operating profit margin at 49.2%, driven by HER2 franchise and key product launches like Phesgo (48% growth) and Xolair (CHF 3B revenue).
  • Strong R&D Pipeline Momentum:: 10 new molecular entities (NMEs) entering Phase III trials in 2026, including giredestrant (breast cancer, HR 0.7) and fenebrutinib (MS), alongside 66 NMEs in total, reflecting record R&D expansion.
  • U.S. Strategic Investment:: Committed $50B in U.S. investments over 5 years for R&D, manufacturing, and infrastructure, securing tariff exemptions and Medicaid rebate commitments to support long-term competitiveness.
  • Diagnositcs Headwinds & Recovery:: Diagnostics sales grew 2% (CHF 13.8B), but China pricing reforms caused a 24% decline; however, non-China regions saw 9% (North America) to 11% (Latin America) growth, with margin recovery expected in 2026.
  • EPS & Margin Expansion:: Core EPS up 11% with a 1.9ppt margin improvement to 39.2%, despite CHF 700M LOE impacts, reflecting cost discipline and pricing power, with 2026 guidance targeting high-single-digit EPS growth.

Segment Performance

Pharma sales growth was driven by key products, including Phesgo, which achieved 48% growth, and Xolair, which grew 32% to CHF 3 billion. Oncology sales increased 2% to CHF 15.3 billion, primarily driven by the HER2 franchise. The hematology franchise delivered 15% growth, reaching CHF 8.6 billion in sales, driven by Hemlibra and Polivy. Neurology sales grew 11% to CHF 9.8 billion, driven by Ocrevus, which crossed the CHF 7 billion milestone.

Pipeline Progress

The company made significant progress in its pipeline, with several positive readouts announced, including Phase III studies for fenebrutinib, Enspryng, and Gazyva. Giredestrant, a next-generation endocrine therapy, showed positive results in adjuvant ER-positive HER2-negative breast cancer, with a hazard ratio of 0.7. The company expects to file for U.S. approval later this year. Additionally, the company reported progress on its CVRM pipeline, including positive results for CT-388 in obesity, with a placebo-adjusted weight loss of 22.5%.

Outlook and Valuation

Roche expects mid-single-digit sales growth and high single-digit core EPS growth in 2026. The company's guidance is supported by a strong pipeline, with 10 NMEs moving into Phase III. The current valuation metrics, including a P/E Ratio of 21.86 and an EV/EBITDA of 21.1, indicate a premium valuation. Analysts estimate next year's revenue growth at 3.8%, which is lower than the current year's growth rate. The company's dividend yield of 2.77% provides a relatively stable return.

Diagnostics Division

The Diagnostics division reported sales of CHF 13.8 billion, a 2% growth or CHF 292 million compared to 2024 at constant exchange rates. Excluding the impact of healthcare pricing reforms in China, the growth was 7%. The company saw strong growth in North America (9%), EMEA (6%), and Latin America (11%), but a decline of 12% in Asia Pacific due to China's 24% decline. Roche expects to grow its Diagnostics division sales at a mid-single-digit rate in 2026.

Key Developments

The company has a number of key developments expected in 2026, including the launch of several new products, such as the AXELIOS Sequencing Solution, Elecsys pTau 217, and Elecsys Neurofilament light chain. The company is also expected to initiate Phase III trials for CT-388 in obesity and report data from the MAJESTY trial in membranous nephropathy.

3. NewsRoom

Card image cap

Roche Multiple Sclerosis Drug Meets Main Goal in Late-Stage Trial

Mar -02

Source:

Card image cap

Roche Multiple Sclerosis Drug Meets Key Goal in Late-Stage Trial

Mar -02

Source:

Card image cap

Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

Mar -02

Source:

Card image cap

[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)

Mar -02

Source:

Card image cap

Olema Pharmaceuticals CEO Touts Palazestrant Edge as Oral SERDs Shake Out at Conference

Mar -01

Source:

Card image cap

Roche Advances Oncology And Kidney Pipeline As Valuation Signals Upside Potential

Feb -28

Source:

Card image cap

Merck Stock, Up 13% In 2026, Ticks Another Box. Is It Now A Buy?

Feb -27

Source: investors.com

Card image cap

Recursion Pharmaceuticals (RXRX) Hits Clinical Milestones as 2025 Revenue Grows to $74.7M

Feb -26

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (4.22%)

6. Segments

Pharmaceuticals - Roche Pharmaceuticals

Expected Growth: 4.0%

Roche Pharmaceuticals' 4.0% growth is driven by strong sales of its innovative medicines, particularly in cancer and immunology. Key products like Tecentriq and Perjeta have contributed significantly to revenue growth. Additionally, the company's robust pipeline and strategic acquisitions have enhanced its market position, enabling it to maintain a competitive edge in the pharmaceutical industry.

Pharmaceuticals - Chugai

Expected Growth: 4.0%

Chugai's growth is driven by strong sales of its flagship products, including olipop (constipation treatment) and Xofluza (influenza treatment). Roche Holding AG's strategic focus on innovative medicines and expansion into emerging markets also contribute to Chugai's 4.0% growth. Increasing demand for its portfolio of medicines, particularly in Asia, fuels the company's growth trajectory.

Diagnostics

Expected Growth: 3.5%

Roche Holding AG's diagnostics segment growth of 3.5% is driven by strong sales of its molecular diagnostic solutions, particularly COVID-19 testing products, and increased demand for its laboratory information systems, offset by declines in traditional diagnostic products.

Elimination

Expected Growth: 0.0%

The elimination from Roche Holding AG with 0.0% growth likely stems from declining sales or market share erosion due to increased competition, patent expirations, or unsuccessful product launches, ultimately affecting the company's revenue and growth prospects.

7. Detailed Products

Diagnostics

Roche Diagnostics is a global leader in in vitro diagnostics, offering a broad portfolio of diagnostic solutions for healthcare professionals.

Pharmaceuticals

Roche Pharmaceuticals develops and commercializes innovative medicines for oncology, immunology, ophthalmology, and neuroscience.

Sequencing Solutions

Roche Sequencing Solutions provides next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies for research and diagnostics.

Molecular Diagnostics

Roche Molecular Diagnostics offers a range of molecular diagnostic tests for infectious diseases, cancer, and genetic disorders.

Tissue Diagnostics

Roche Tissue Diagnostics provides instruments and reagents for tissue-based cancer diagnostics and research.

Point of Care

Roche Point of Care offers handheld and benchtop analyzers for near-patient testing in hospitals, clinics, and physician offices.

8. Roche Holding AG's Porter Forces

Forces Ranking

Threat Of Substitutes

Roche Holding AG has a moderate threat of substitutes due to the presence of alternative pharmaceutical companies and generic drug manufacturers. However, the company's strong brand reputation and patented products mitigate this threat to some extent.

Bargaining Power Of Customers

Roche Holding AG has a low bargaining power of customers due to its strong brand reputation and patented products, which gives the company significant pricing power. Additionally, the company's products are often reimbursed by healthcare systems, reducing the bargaining power of individual customers.

Bargaining Power Of Suppliers

Roche Holding AG has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and services. However, the company's large scale of operations and long-term contracts with suppliers mitigate this threat to some extent.

Threat Of New Entrants

Roche Holding AG has a low threat of new entrants due to the high barriers to entry in the pharmaceutical industry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise.

Intensity Of Rivalry

Roche Holding AG operates in a highly competitive pharmaceutical industry, with several large multinational corporations competing for market share. The company's strong brand reputation, patented products, and significant research and development investments help to mitigate this threat to some extent.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 50.16%
Debt Cost 3.95%
Equity Weight 49.84%
Equity Cost 4.72%
WACC 4.33%
Leverage 100.63%

11. Quality Control: Roche Holding AG passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Novartis

A-Score: 6.5/10

Value: 3.0

Growth: 4.2

Quality: 8.3

Yield: 7.5

Momentum: 6.5

Volatility: 9.3

1-Year Total Return ->

View Full Report
Stock-Card
GSK

A-Score: 6.3/10

Value: 4.7

Growth: 2.2

Quality: 7.1

Yield: 6.9

Momentum: 9.0

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Sanofi

A-Score: 5.9/10

Value: 6.2

Growth: 4.0

Quality: 8.0

Yield: 7.5

Momentum: 2.5

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
AstraZeneca

A-Score: 5.9/10

Value: 1.3

Growth: 7.6

Quality: 6.8

Yield: 3.1

Momentum: 9.0

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
Roche

A-Score: 5.4/10

Value: 1.1

Growth: 3.0

Quality: 6.4

Yield: 5.6

Momentum: 8.5

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Bayer

A-Score: 4.4/10

Value: 7.0

Growth: 2.1

Quality: 2.7

Yield: 3.1

Momentum: 8.5

Volatility: 3.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

356.1$

Current Price

356.1$

Potential

-0.00%

Expected Cash-Flows